Christian Rubio, vice president of Strategic Advancement for Global Genes, explains why supporting more diversity in clinical trials is both good science and good morals and outlines how researchers can take strides towards greater inclusion of underrepresented populations. He also delves into the current state of rare disease research and COVID-19’s impact on the field.